1. Home
  2. ADVB vs INTS Comparison

ADVB vs INTS Comparison

Compare ADVB & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVB
  • INTS
  • Stock Information
  • Founded
  • ADVB 2014
  • INTS 2012
  • Country
  • ADVB United States
  • INTS United States
  • Employees
  • ADVB N/A
  • INTS N/A
  • Industry
  • ADVB Medical Specialities
  • INTS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADVB Health Care
  • INTS Health Care
  • Exchange
  • ADVB Nasdaq
  • INTS Nasdaq
  • Market Cap
  • ADVB 9.1M
  • INTS 8.4M
  • IPO Year
  • ADVB 2025
  • INTS 2023
  • Fundamental
  • Price
  • ADVB $0.42
  • INTS $0.28
  • Analyst Decision
  • ADVB
  • INTS Strong Buy
  • Analyst Count
  • ADVB 0
  • INTS 4
  • Target Price
  • ADVB N/A
  • INTS $4.50
  • AVG Volume (30 Days)
  • ADVB 371.2K
  • INTS 3.8M
  • Earning Date
  • ADVB 11-03-2025
  • INTS 08-07-2025
  • Dividend Yield
  • ADVB N/A
  • INTS N/A
  • EPS Growth
  • ADVB N/A
  • INTS N/A
  • EPS
  • ADVB N/A
  • INTS N/A
  • Revenue
  • ADVB N/A
  • INTS N/A
  • Revenue This Year
  • ADVB N/A
  • INTS N/A
  • Revenue Next Year
  • ADVB N/A
  • INTS N/A
  • P/E Ratio
  • ADVB N/A
  • INTS N/A
  • Revenue Growth
  • ADVB N/A
  • INTS N/A
  • 52 Week Low
  • ADVB $0.34
  • INTS $0.19
  • 52 Week High
  • ADVB $4.10
  • INTS $4.34
  • Technical
  • Relative Strength Index (RSI)
  • ADVB N/A
  • INTS 45.18
  • Support Level
  • ADVB N/A
  • INTS $0.27
  • Resistance Level
  • ADVB N/A
  • INTS $0.32
  • Average True Range (ATR)
  • ADVB 0.00
  • INTS 0.02
  • MACD
  • ADVB 0.00
  • INTS -0.00
  • Stochastic Oscillator
  • ADVB 0.00
  • INTS 29.48

About ADVB Advanced Biomed Inc. Common Stock

Advanced Biomed Inc operates through its subsidiaries that are responsible for the main operation and the design and development of the company's primary technologies and products. It has been focusing on the integration of multiple interdisciplinary technologies and established its microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, the company has developed various advanced and original research through the joint application of semiconductor technology and biotechnology. devices, A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.

About INTS Intensity Therapeutics Inc. Common stock

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Share on Social Networks: